Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to assess the impact of the administration route of dexamethasone (intravenous vs. perineural) on postoperative pain, inflammatory response, and neuromonitoring parameters in pediatric patients undergoing hip surgery. The primary outcome is postoperative pain intensity measured using an age-appropriate pain scale at multiple time intervals. Secondary outcomes include inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), opioid consumption, time to first rescue analgesia, and overall patient recovery. This randomized, double-blinded study seeks to improve pain management strategies and optimize anesthesia protocols in pediatric hip surgery.
Pediatric hip surgery is a complex procedure that can result in significant postoperative pain and an inflammatory response. Effective pain management is critical in this population to promote early mobilization, reduce opioid consumption, and minimize adverse outcomes. The pericapsular nerve group (PENG) block is a regional anesthesia technique that offers targeted analgesia for hip procedures while preserving motor function, making it particularly suitable for pediatric patients.
Dexamethasone is commonly used as an adjuvant in regional anesthesia to prolong analgesia and mitigate inflammation. However, the optimal administration route of dexamethasone in the context of PENG block for pediatric hip surgery remains unclear. This study is designed to compare the efficacy of intravenous versus perineural dexamethasone in prolonging postoperative analgesia and reducing inflammatory responses.
This prospective, randomized, double-blinded clinical trial will enroll pediatric patients undergoing elective hip surgery. Participants will be randomized into two groups: one group will receive intravenous dexamethasone, while the other will receive perineural dexamethasone administered as part of the PENG block. All patients will receive standardized general anesthesia and PENG block using a local anesthetic at a fixed concentration.
The primary outcome will be time to first request rescue analgesia. Secondary outcomes include the inflammatory response measured by NLR and PLR, postoperative pain intensity, assessed using an age-appropriate pain scale at predefined time intervals, total opioid consumption, and blood glucose levels. The study will also monitor neuromonitoring parameters during surgery to ensure patient safety and evaluate the influence of dexamethasone on neurological outcomes.
Safety will be closely monitored throughout the study, with particular attention to potential complications such as local anesthetic systemic toxicity (LAST) or dexamethasone-related adverse events.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| perinerual dexamethasone | Active Comparator | PENG block + perineural dexamethasone |
|
| intravenous dexamethasone | Active Comparator | PENG block + intravenous dexamethasone |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| perineural Dexamethasone 4mg | Drug | PENG block with 0.5ml/kg 0.2% ropivacaine + 0,1mgkg perineural Dexamethasone |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time to first rescue opioid analgesia | Time to first rescue opioid analgesia | 48 hours after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Total opioid consumption | Total opioid consumption in milliequivalents of morphine | 48 hours after surgery |
| NRS | The numeric rating scale (NRS) with zero meaning "no pain" and 10 meaning "the worst pain imaginable." |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Malgorzata Reysner, M.D. Ph.D. | Poznań University of Medical Sciences | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Poznan University of Medical Sciences | Poznan | 60-701 | Poland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006617 | Hip Dislocation |
| ID | Term |
|---|---|
| D004204 | Joint Dislocations |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D014947 | Wounds and Injuries |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| intravenous Dexamethsone 4mg | Drug | PENG block with 0,5ml/kg 0.2% ropivacaine + 0,1mg/kg intravenous Dexamethasone |
|
| 4 hours after surgery |
| NRS | The numeric rating scale (NRS) with zero meaning "no pain" and 10 meaning "the worst pain imaginable." | 8 hours after surgery |
| NRS | The numeric rating scale (NRS) with zero meaning "no pain" and 10 meaning "the worst pain imaginable." | 12 hours after surgery |
| NRS | The numeric rating scale (NRS) with zero meaning "no pain" and 10 meaning "the worst pain imaginable." | 24 hours after surgery |
| NRS | The numeric rating scale (NRS) with zero meaning "no pain" and 10 meaning "the worst pain imaginable." | 48 hours after surgery |
| Nerve damage | Nerve damage assesent will be performed using scale: N0- no nerve damage; N1- minor - sensory paresthesia; N2- majorcomplete sensory anesthesia; N3- Complete- complete motor defect with or without paraesthesia; N4-CRPS- Complex Regional Pain Syndrome | 12 hours after surgery |
| Nerve damage | Nerve damage assesent will be performed using scale: N0- no nerve damage; N1- minor - sensory paresthesia; N2- majorcomplete sensory anesthesia; N3- Complete- complete motor defect with or without paraesthesia; N4-CRPS- Complex Regional Pain Syndrome | 24 hours after surgery |
| Nerve damage | Nerve damage assesent will be performed using scale: N0- no nerve damage; N1- minor - sensory paresthesia; N2- majorcomplete sensory anesthesia; N3- Complete- complete motor defect with or without paraesthesia; N4-CRPS- Complex Regional Pain Syndrome | 48 hours after surgery |
| NLR | Neutrophile-to-lymphocyte ratio | 12 hours after surgery |
| NLR | Neutrophile-to-lymphocyte ratio | 24 hours after surgery |
| NLR | Neutrophile-to-lymphocyte ratio | 48 hours after surgery |
| PLR | Platelet-to-lymphocyte ratio | 12 hours after surgery |
| PLR | Platelet-to-lymphocyte ratio | 24 hours after surgery |
| PLR | Platelet-to-lymphocyte ratio | 48 hours after surgery |
| glucose | blood glucose levels | 12 hours after surgery |
| glucose | blood glucose levels | 24 hours after surgery |
| glucose | blood glucose levels | 48 hours after surgery |
| D025981 |
| Hip Injuries |